Biocaptiva, an Edinburgh university cancer research spin-out, has appointed life sciences specialist Stephane Argivier as chair to steer its next phase of international growth.
The company’s patented msX platform has the potential to improve the pace and scale of cancer research by addressing a long-standing bottleneck in how samples are prepared for liquid biopsy..
Bringing 30 years’ experience, including 15 years at board level, Mr Argivier has built a career leading private, venture-backed and growth-stage businesses through periods of transformation, with particular expertise in strategy, commercial scale-up, governance, fundraising, organisational development and founder transitions.
The Frenchman takes the Biocaptiva chair from Frank Armstrong, who served since the company’s inception, steering the business through its early technological, organisational and strategic development to lay solid foundations for commercial growth.
The appointment follows a series of significant milestones for Biocaptiva, including a £1.5m funding deal led by existing investor Archangels and supported by Old College Capital, BBI, Scottish Enterprise and EverQuest Partners.
#Biocaptiva #hires #life #sciences #veteran #chair #Daily #Business